• español
    • English
  • Login
  • English 
    • español
    • English

UniversidaddeCádiz

Área de Biblioteca, Archivo y Publicaciones
Communities and Collections
View Item 
  •   RODIN Home
  • Producción Científica
  • Artículos Científicos
  • View Item
  •   RODIN Home
  • Producción Científica
  • Artículos Científicos
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Safety and efficacy of convalescent plasma for COVID-19 in the pre-vaccine era, and implementation in a large healthcare system: A phase I/II randomized, multicentre clinical trial (PC-COVID)

Thumbnail
Identificadores

URI: http://hdl.handle.net/10498/40626

DOI: 10.1016/J.EIMC.2026.503166

ISSN: 1578-1852

ISSN: 0213-005X

Files
OA_2026_0606.pdf (1.065Mb)
Statistics
View statistics
Metrics and citations
 
Share
Export
Export reference to MendeleyRefworksEndNoteBibTexRIS
Metadata
Show full item record
Author/s
Caponcello, Maria Giulia; Macías Sánchez, Maria del Mar; Macías, Juan; Aguilar Guisado, Manuela; Romero Palacios, AlbertoAuthority UCA; Retamar Gentil, Pilar; Márquez-Gómez, Ignacio; Martínez-Marcos, Francisco Javier; López Cardenas, SalvadorAuthority UCA; Marrugal Lorenzo, Jose Antonio; Quijano Ruiz, Blanca; Mata, Rosario; Carmona Sánchez, Gloria; Oyonarte, Salvador; Rodríguez Baño, Jesús
Date
2026-03-31
Department
Cirugía; Medicina
Source
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 44, Núm. 6, 2026
Abstract
Introduction: A phase 2 trial was conducted to evaluate the safety and efficacy of convalescent plasma (CP) for patients admitted with COVID-19 in the pre-vaccine era. Methods: CP was compared to standard of care (SoC) in a randomized clinical trial in patients admitted with COVID-19 pneumonia and with either hypoxia and/or some underlying condition from April to December 2020 in 15 hospitals in Andalusia, Spain. The primary endpoints were adverse events and failure (all-cause death and need for mechanical ventilation during the first 21 days). Result: The procedure for CP was developed and worked properly. Overall, 72 patients of 88 evaluated were recruited (37 and 35) assigned to CP and SoC. Median duration of COVID-19 related symptoms was 7 and 6 days, and median oxygen saturation at randomization was 93% and 92.5% in experimental and control arms, respectively. Overall, 8 (21.6%) patients in the experimental CP group (non related to CP) and 8 (22.9%) in the control group developed grade 3 adverse events (relative risk [RR] 0.94; 95% CI: 0.39–2.24); failure occurred in 3 (8.1%) and 4 (11.4%) patients, respectively ([RR] 0.94, CI: 0.14–6.35 for both events). No differences in secondary endpoints (change in inflammatory parameters, negativization of SARS-CoV-2 PCR or duration of hospital stay) were found. Conclusions: The results suggested that CP is safe for use in COVID-19 patients, although no significant efficacy signal could be observed. A successful regional system for CP administration was developed.
Subjects
COVID-19; Convalescent plasma; Clinical trial
Collections
  • Artículos Científicos [12034]
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This work is under a Creative Commons License Attribution-NonCommercial-NoDerivatives 4.0 Internacional

Browse

All of RODINCommunities and CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

LoginRegister

Statistics

View Usage Statistics

Información adicional

AboutDeposit in RODINPoliciesGuidelinesRightsLinksStatisticsNewsFrequently Asked Questions

RODIN is available through

OpenAIREOAIsterRecolectaHispanaEuropeanaBaseDARTOATDGoogle Academic

Related links

Sherpa/RomeoDulcineaROAROpenDOARCreative CommonsORCID

RODIN está gestionado por el Área de Biblioteca, Archivo y Publicaciones de la Universidad de Cádiz

Contact informationSuggestionsUser Support